Preclinical studies and in human fibroblasts have suggested that inhibitors of S6K1 should be considered for therapeutic intervention in FXS [76–79]; however, this knowledge nor this target biomarker has been successfully applied to human clinical trials. The gene discussed is RPS6KB1; the disease is fragile X syndrome.